Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Anthem Inc. CORP UNIT 050118
ANTX | US
1.08
USD0.03
2.86%
ANTX | US
About Anthem Inc. CORP UNIT 050118
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.08
Open
1.06
High
1.12
Low
1.06
AN2 Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing treatments for rare chronic and serious infectious diseases. It is developing epetraborole which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park California.
View LessANTX | US
Risk
24.9
Sharpe
-0.82
Luna's Score
52/100
Recommendation
Hold
Luna says (ANTX | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
30.5%1 month
24.9%3 months
128.1%6 months
105.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.32
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
32.23M
MarketCap(USD)
32.23M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-69.48
Short ratio
0.75
Short perc.
0.98
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.09
Range1M
0.09
Range3M
2.08
Volumes: Market Activity
Rel. volume
3.51
Price X volume
681.55K
